lobbying_activities: 2461156
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2461156 | c785f7de-5fb6-465c-9d6b-bc371e139be7 | Q2 | RED+BLUE STRATEGIES | 400693064 | COHERUS BIOSCIENCES | 2020 | second_quarter | PHA | Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. H.R. 6800 - The HEROES Act - Issues related to lowering costs of prescription drugs for Americans. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2020-07-03T15:47:09.990000-04:00 |